Related Experiment Video
Updated: Mar 24, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
One Versus Two Months Anticoagulation After Catheter Ablation for Atrial Fibrillation in Patients Who Were Not
Nilar Aung1, Soyoon Park2, Soohyun Kim3
1Cardiac Medical Unit, No. 1. Defense Services General Hospital, Yangon, Myanmar.
Insights
One month of oral anticoagulant therapy after catheter ablation appears safe for low-risk atrial fibrillation patients. This pilot study found no increased risk of stroke or systemic embolism, suggesting shorter treatment durations may be viable.
Area of Science:
- Cardiology
- Electrophysiology
- Clinical Trials
Background:
- Low-risk atrial fibrillation (AF) patients often receive prolonged oral anticoagulant (OAC) therapy post-catheter ablation (CA) without strong evidence.
- The necessity of extended OAC in specific low-risk AF populations remains unclear.
Purpose of the Study:
- To evaluate the safety and efficacy of 1-month versus 2-month OAC therapy after successful CA in low-risk AF patients.
- To determine if a shorter OAC duration impacts the incidence of stroke or systemic embolism.
Main Methods:
- A pilot randomized trial (REDUCIBLE trial) comparing 1-month vs. 2-month OAC post-CA.
- Inclusion criteria: men with CHA₂DS₂-VASc score ≤1, women with ≤2.
- Primary outcome: incidence of stroke and systemic embolism within 1 year.
Main Results:
- 220 patients were randomized; baseline characteristics were similar.
- No ischemic stroke or systemic embolism occurred in either group over 1 year.
- Atrial fibrillation recurrence-free survival rates were comparable between the 1-month and 2-month OAC groups (76.9% vs. 77.7%).
Conclusions:
- One month of OAC post-ablation is not associated with a significant increase in stroke or systemic embolism risk in low-risk AF patients.
- Larger trials are needed to confirm these findings and establish definitive conclusions.
- Shorter OAC durations warrant further investigation in carefully selected AF patient cohorts.
Background And Objectives:
Even low-risk atrial fibrillation (AF) patients usually continue anticoagulant therapy for several months after the procedure. However, there is no solid evidence supporting this practice. The REDUCIBLE trial is designed to compare the outcomes of conventional 2- versus 1-month oral anticoagulant (OAC) therapy following successful catheter ablation (CA) in men with a CHA₂DS₂-VASc score of ≤1 and women with ≤2, where long-term OAC is not recommended.
Methods:
In this pilot study, patients undergoing CA for drug-refractory paroxysmal AF were randomly divided into 2 groups. One group received OAC for 1 month, whereas the other received it for 2 months. The primary outcome was the incidence of stroke and systemic embolism within 1 year after ablation.
Results:
A total of 220 patients were enrolled and randomly assigned to 2 groups. Baseline characteristics were similar between the groups. The AF recurrence-free survival (RFS) rate was similar (76.9% vs. 77.7%, p=0.98). During the blanking period, AF RFS was also similar (92.5% vs. 92.9%, p=0.98). No ischemic stroke or systemic embolism occurred in either group during 1-year follow-up. One patient in the 1-month group experienced a minor bleeding event when anticoagulants were not taken (7 months after ablation).
Conclusions:
This study found that a single month of OAC post-ablation did not significantly elevate the risk of stroke or systemic embolism in low-risk patients. Nonetheless, a larger sample size would be necessary to achieve the statistical power for definitive conclusions. Future larger prospective clinical trials are needed to address this question comprehensively.
Trial Registration:
ClinicalTrials.gov Identifier: NCT03573037.
Related Concept Videos
01:26Cardiac Catheterization IV: Nursing Management
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias